This course will explain in brief the mechanism of action and some ADA Guidelines for use of some of the newest agents to treat type 2 diabetes: the SGLTs and the GLPs Some of the most robust studies will be outlined, but the course is meant to give a brief, simple synopsis of these groundbreaking therapies.